All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is pleased to present a visual abstract summarizing results from the phase III TRIANGLE trial (NCT02858258) assessing the safety and efficacy of the addition of ibrutinib, a Bruton’s tyrosine kinase inhibitor, to standard immunochemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) in younger patients with mantle cell lymphoma. Results from this trial were published by Dreyling et al.1 in The Lancet.
The addition of ibrutinib to standard immunochemotherapy improved outcomes; however, toxicity was increased when ibrutinib was given after auto-HSCT.1 Whether auto-HSCT is beneficial with ibrutinib-based treatment is yet to be determined.1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox